Mads Buhl Axelsen
Director Técnico/Científico/I+D en GUBRA A/S .
Perfil
Mads Buhl Axelsen is currently working as the Chief Medical Officer at Gubra A.
Previously, he held positions as Director at Aros Pharma ApS, Principal at Novo Nordisk A and Leo Co. Ltd., Chief Clinical Officer at Azanta Danmark A, and Chief Medical Officer at Neurokey A.
Dr. Axelsen obtained a doctorate degree from the University of Copenhagen in 1988.
Cargos activos de Mads Buhl Axelsen
Empresas | Cargo | Inicio |
---|---|---|
GUBRA A/S | Director Técnico/Científico/I+D | 01/08/2022 |
Antiguos cargos conocidos de Mads Buhl Axelsen.
Empresas | Cargo | Fin |
---|---|---|
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Director Técnico/Científico/I+D | 30/07/2010 |
Aros Pharma ApS
Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Director/Miembro de la Junta | - |
Leo Co. Ltd. | Corporate Officer/Principal | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - |
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Director Técnico/Científico/I+D | - |
Formación de Mads Buhl Axelsen.
University of Copenhagen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
GUBRA A/S | Commercial Services |
Empresas privadas | 4 |
---|---|
Leo Co. Ltd. | Retail Trade |
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Health Technology |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
Aros Pharma ApS
Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Mads Buhl Axelsen